Tip:
Highlight text to annotate it
X
>>> DR. DAVID MARGILETH: The Oncotype DX has I think changed the treatment decisions in
patients with hormone receptor-positive, lymph node-negative, HER2-negative breast cancer.
It allows us to individualize or personalize that treatment decision such that in the majority
of cases, we can be very clear that chemotherapy either will help, and in that group it helps
a lot, or that it’s absolutely unnecessary. I have been a big adapter of oncotype for
a long time. I can’t imagine it not being used in general in most women with that subset
of breast cancer. We have seen a number of second opinions where women have been scheduled
to start chemotherapy and have not had an oncotype test, and sometimes we get the oncotype
and find out that that planned chemotherapy would have been totally unnecessary, and that’s
obviously very beneficial. So oncotype is a big part of my practice in those patients
for which it should be used. Hi, I am Dr. Jay Harness and I want to share
with you important information that I believe that every newly diagnosed patient with breast
cancer needs to know.
Susan Denver: I am a breast cancer survivor.
Katherine Stockton: I am a breast cancer survivor.
Coree: I am a breast cancer survivor.
Susan Denver: And I want every woman to know…
Katherine Stockton: …about personalized breast cancer treatment…
Susan Denver: …and the genomic test.
Coree: A test that helps guide a woman and her doctor…
Katherine Stockton: …to the best treatment options for her.
Susan Denver: Pass it on!